- GlobeNewswire•2 days agoMomenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., Feb. 17, 2017-- Momenta Pharmaceuticals, Inc., announced today that is has changed the time for its fourth quarter and year end 2016 earnings conference call and webcast. Momenta will ...
- GlobeNewswire•2 days agoMomenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues. Warning letter does not restrict the production or shipment of Glatopa 20 mg. CAMBRIDGE, Mass., ...
- GlobeNewswire•2 days ago
CAMBRIDGE, Mass., Feb. 17, 2017-- Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable ...
MNTA : Summary for Momenta Pharmaceuticals, Inc. - Yahoo Finance
Momenta Pharmaceuticals, Inc. (MNTA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||16.50 x 500|
|Ask||18.00 x 100|
|Day's Range||18.60 - 19.25|
|52 Week Range||7.86 - 19.90|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-14.18|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|